OneSource Specialty Pharma Inc Stock Price Today (NSE: ONESOURCE)
Fundamental Score
OneSource Specialty Pharma Inc Share Price — Live NSE/BSE Price, Fundamentals & Analysis
OneSource Specialty Pharma Inc share price today is ₹1473.30, up +8.47% on NSE/BSE as of 30 March 2026. OneSource Specialty Pharma Inc (ONESOURCE) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹18.39K (Cr). The 52-week high for ONESOURCE share price is ₹2248.00 and the 52-week low is ₹1057.00. At a P/E ratio of 133.33x, ONESOURCE is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 3.34% and a debt-to-equity ratio of 0.22.
OneSource Specialty Pharma Inc Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
OneSource Specialty Pharma Inc Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
OneSource Specialty Pharma Inc Share Price: A Data-Driven ROCE Efficiency Analysis
The pharmaceutical industry, often characterized by its intensive research and development cycles, faces a constant need to optimize capital allocation for long-term growth. This analysis examines the financial health of OneSource Specialty Pharma Inc, focusing particularly on its Return on Capital Employed (ROCE). Currently, the OneSource Specialty Pharma Inc share price stands at ₹1119.900024, accompanied by a Price-to-Earnings (PE) ratio of 133.33 and an ROCE of 5.52%. This analysis is part of an 80-parameter fundamental audit verified by Sweta Mishra.
The relatively high PE ratio of 133.33 suggests that investors have high expectations for future earnings growth. However, the ROCE of 5.52% warrants closer scrutiny. ROCE measures how efficiently a company utilizes its capital to generate profits. A lower ROCE, relative to peers, can indicate inefficiencies in asset utilization, cost management, or pricing strategies. This figure becomes especially important when we consider that other pharmaceutical firms might be generating higher returns on their investments.
Comparing OneSource Specialty Pharma Inc to sector peers like
Mankind Pharma Ltd provides valuable context. While specific data for peer ROCE is unavailable here, variations in ROCE often reflect differences in management quality and operational efficiency. For example, differences in marketing strategy, distribution networks or product innovation are indicators of the quality of management and efficient capital deployment.The 5.52% ROCE of OneSource Specialty Pharma Inc directly impacts its long-term competitive advantage, or "moat." A consistently low ROCE may hinder the company's ability to reinvest profits for expansion, research and development, or acquisitions. This could potentially weaken its market position over time, especially if competitors are generating higher returns and can therefore invest more aggressively. Continued monitoring of ROCE and its drivers is crucial for understanding the long-term sustainability of OneSource Specialty Pharma Inc's business model.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
OneSource Specialty Pharma Inc Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ONESOURCE across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (127.55%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Conservative Debt Levels (D/E: 0.22)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Institutional Confidence (FII+DII: 37.87%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
8 factors identified
Below-Average Return on Equity (3.34%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (5.52%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 133.33x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Interest Coverage (1.87x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-1969.92 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (29.77%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
High Share Pledging Risk (26.04%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
OneSource Specialty Pharma Inc Financial Statements
Comprehensive financial data for OneSource Specialty Pharma Inc including income statement, balance sheet and cash flow
About ONESOURCE (OneSource Specialty Pharma Inc)
OneSource Specialty Pharma Inc. is a dynamic pharmaceutical company dedicated to innovating and improving patient lives through specialized drug development and commercialization. ...Focused on niche therapeutic areas, OneSource concentrates its efforts on creating targeted solutions for complex medical conditions where unmet needs persist. Their approach emphasizes rigorous scientific research, cutting-edge formulation technologies, and strategic partnerships to bring high-quality, effective medications to market. The company operates with a commitment to ethical practices and prioritizes patient safety and well-being in every aspect of its operations. OneSource distinguishes itself within the pharmaceutical landscape by integrating research and development with advanced manufacturing capabilities. This synergy allows for streamlined product development cycles, ensuring efficient progression from laboratory to patient. The company's state-of-the-art facilities are equipped to handle a diverse range of dosage forms and delivery systems, including both oral and injectable medications. Furthermore, OneSource actively seeks collaborations with academic institutions and other pharmaceutical companies to leverage expertise and accelerate the discovery and development of novel therapies. Driven by a team of experienced scientists, clinicians, and business professionals, OneSource is committed to expanding its product portfolio and geographic reach. The company's strategic vision involves identifying and capitalizing on emerging market opportunities, while maintaining a steadfast dedication to scientific rigor and patient-centric values. As OneSource continues to grow, it remains dedicated to making a meaningful impact on global healthcare by providing innovative, specialized pharmaceuticals that improve patient outcomes and enhance the quality of life.
Company Details
Key Leadership
ONESOURCE Share Price: Frequently Asked Questions
What is the current share price of OneSource Specialty Pharma Inc (ONESOURCE)?
As of 30 Mar 2026, 12:07 pm IST, OneSource Specialty Pharma Inc share price is ₹1473.30. The ONESOURCE stock has a market capitalisation of ₹18.39K (Cr) on NSE/BSE.
Is ONESOURCE share price Overvalued or Undervalued?
ONESOURCE share price is currently trading at a P/E ratio of 133.33x, compared to the industry average of 31.77x. Based on this relative valuation, the OneSource Specialty Pharma Inc stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of ONESOURCE share price?
The 52-week high of ONESOURCE share price is ₹2248.00 and the 52-week low is ₹1057.00. These values are updated daily from NSE/BSE price data.
What factors affect the OneSource Specialty Pharma Inc share price?
Key factors influencing ONESOURCE share price include quarterly earnings growth (Sales Growth: 12.49%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is OneSource Specialty Pharma Inc a good stock for long-term investment?
OneSource Specialty Pharma Inc shows a 5-year Profit Growth of N/A% and an ROE of 3.34%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.22 before investing in ONESOURCE shares.
How does OneSource Specialty Pharma Inc compare with its industry peers?
OneSource Specialty Pharma Inc competes with major peers in the Pharmaceuticals. Investors should compare ONESOURCE share price P/E of 133.33x and ROE of 3.34% against the industry averages to determine competitive standing.
What is the P/E ratio of ONESOURCE and what does it mean?
ONESOURCE share price has a P/E ratio of 133.33x compared to the industry average of 31.77x. Investors pay ₹133 for every ₹1 of annual earnings.
How is ONESOURCE performing according to Bull Run's analysis?
ONESOURCE has a Bull Run fundamental score of 5.5/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ONESOURCE belong to?
ONESOURCE operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting OneSource Specialty Pharma Inc share price.
What is Return on Equity (ROE) and why is it important for ONESOURCE?
ONESOURCE has an ROE of 3.34%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently OneSource Specialty Pharma Inc generates profits from shareholders capital.
How is ONESOURCE debt-to-equity ratio and what does it indicate?
ONESOURCE has a debt-to-equity ratio of 0.22, which indicates conservative financing with low financial risk.
What is ONESOURCE dividend yield and is it a good dividend stock?
ONESOURCE offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in OneSource Specialty Pharma Inc shares.
How has ONESOURCE share price grown over the past 5 years?
ONESOURCE has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in ONESOURCE and why does it matter?
Promoters hold 29.77% of ONESOURCE shares, with 26.04% pledged. High promoter holding often indicates strong management confidence in OneSource Specialty Pharma Inc.
What is ONESOURCE market capitalisation category?
ONESOURCE has a market capitalisation of ₹18392 crores, placing it in the Mid-cap category.
How volatile is ONESOURCE stock?
ONESOURCE has a beta of N/A. A beta > 1 suggests the OneSource Specialty Pharma Inc stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ONESOURCE operating profit margin trend?
ONESOURCE has a 5-year average Operating Profit Margin (OPM) of 8.21%, indicating the company's operational efficiency.
How is ONESOURCE quarterly performance?
Recent quarterly performance shows OneSource Specialty Pharma Inc YoY Sales Growth of 12.49% and YoY Profit Growth of 127.55%.
What is the institutional holding pattern in ONESOURCE?
ONESOURCE has FII holding of 19.39% and DII holding of 18.48%. Significant institutional holding often suggests professional confidence in the OneSource Specialty Pharma Inc stock.